Peptides Community
Regulation · EU/EEA
R 0072026-08-06

European Union and EEA peptide regulation

Executive summary

The EU pharmaceutical framework — Directive 2001/83/EC and Regulation (EC) 726/2004 — governs peptides as medicinal products. The European Medicines Agency (EMA) evaluates centrally authorised peptide drugs; individual member states authorise others through mutual recognition or decentralised procedures. Pharmacy compounding is regulated at member-state level. The EU Cosmetics Regulation (EC) 1223/2009 covers peptides in cosmetic products.

Approved medicines

Centrally authorised peptide drugs include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), insulin analogues, teriparatide, leuprolide, octreotide, and many others.

Biologically derived peptides (rDNA production) fall under the mandatory centralised procedure. Chemically synthesised peptides may use the centralised procedure voluntarily or follow national/MRP/DCP pathways.

Source: EMA Medicines Search, https://www.ema.europa.eu/en/medicines

Investigational use

Clinical trials require authorisation under the Clinical Trials Regulation (EU) 536/2014 (effective 31 January 2022). Sponsors must submit a Clinical Trial Application through the EU Clinical Trials Information System (CTIS).

Compounding/manufacturing

  • Article 3(1) of Directive 2001/83/EC exempts magistral formulae (prepared in a pharmacy per a prescription for an identified patient) from marketing authorisation.

  • Article 3(2) exempts officinal formulae (prepared per pharmacopoeia, supplied directly to the pharmacy's own patients).

  • CJEU judgment Abcur (C-544/13 and C-545/13): prescription must be prior to preparation; patient must be identified before production. Stock preparation for unspecified patients is industrial manufacture, not compounding.

  • Council of Europe Resolution CM/Res(2011)1 provides non-binding quality guidance for pharmacy preparations.

  • Member state variation is significant: Germany, France, and the Netherlands have developed pharmacy preparation sectors; others restrict compounding to extemporaneous only. Peptide compounding is highly variable.

Import, sale, advertising, and online supply

  • Import: requires a Manufacturing/Import Authorisation (MIA). Every batch must be certified by a Qualified Person (QP) in the EU/EEA. Active substances must be manufactured to EU-equivalent GMP standards.

  • Online sale: the Falsified Medicines Directive (2011/62/EU) requires the common logo on every webpage offering medicinal products. Clicking the logo must redirect to the national competent authority's register of authorised online retailers. Most member states prohibit online sale of prescription-only medicines.

  • Advertising: prescription-only medicines cannot be advertised to the public (Directive 2001/83/EC, Title VIII).

Research-use-only products

No specific EU-level exemption exists for "research chemicals." If a product meets the medicinal product definition (making therapeutic or physiological claims), it is a medicine and requires a marketing authorisation. Member state enforcement agencies can take action under national law.

Sport/anti-doping overlay

WADA Prohibited List applies through national anti-doping organisations in each EU/EEA member state.

Cosmetics

Regulation (EC) 1223/2009 covers peptide ingredients in cosmetics. Peptide ingredients must be listed in INCI. The boundary with medicinal products is determined by claims and physiological effect. Regulation (EU) 2024/858 addressed nanomaterials in cosmetics, specifically banning acetyl heptapeptide-9 colloidal gold (nano) and acetyl tetrapeptide-17 colloidal platinum (nano) from the EU market as of February 2025 due to insufficient safety data.

Source: https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en

Novel foods

Regulation (EU) 2015/2283 covers novel foods. Peptide hydrolysates and isolated peptides may require novel food authorisation (EFSA assessment + Commission implementing regulation) if not consumed in the EU to a significant degree before May 15, 1997. The boundary with medicinal products applies — the same substance cannot be both a medicine and a food.

Enforcement examples and uncertainty

  • Member state enforcement against peptide sales varies widely; some have active programmes targeting "research chemical" websites, others do not.

  • The distinction between compounding (Art. 3 exemption) and industrial manufacture remains subject to case-by-case interpretation post-Abcur.

  • Compounding of GLP-1 peptides using imported bulk substances raises quality and legal questions in most member states.

Practical interpretation limits

This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.

Primary sources

  1. Directive 2001/83/EC (consolidated). https://eur-lex.europa.eu/eli/dir/2001/83

  2. Regulation (EC) 726/2004 (consolidated). https://eur-lex.europa.eu/eli/reg/2004/726

  3. Regulation (EC) 1223/2009 (consolidated). https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX%3A02009R1223-20260501

  4. Regulation (EU) 2015/2283 (novel foods). https://eur-lex.europa.eu/eli/reg/2015/2283

  5. Directive 2011/62/EU (FMD). https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A32011L0062

  6. EMA Medicines Search. https://www.ema.europa.eu/en/medicines

  7. EMA Synthetic Peptide Guideline (effective June 2026). https://www.ema.europa.eu/en/development-manufacture-synthetic-peptides-scientific-guideline

  8. CJEU Abcur (C-544/13 and C-545/13). https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=ecli:ECLI:EU:C:2015:481

  9. EDQM CEP. https://www.edqm.eu/en/certification

  10. CM/Res(2011)1. https://rm.coe.int/168065c132